Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,345 | -6,854 | -2,947 | -17,240 | -14,622 |
| Depreciation Amortization | 37 | 25 | 12 | 53 | 40 |
| Accounts payable and accrued liabilities | 389 | 740 | 63 | -60 | 148 |
| Other Working Capital | -222 | -357 | -508 | -791 | 67 |
| Other Operating Activity | 2,003 | 987 | 150 | 8,910 | 7,946 |
| Operating Cash Flow | $-8,138 | $-5,459 | $-3,230 | $-9,128 | $-6,420 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -7 | N/A | -8 | -8 |
| Investing Cash Flow | $-9 | $-7 | $N/A | $-8 | $-8 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,686 | 348 | N/A | 11,337 | 11,337 |
| Other Financing Activity | -14 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $4,672 | $348 | $N/A | $11,337 | $11,337 |
| Beginning Cash Position | 12,691 | 12,691 | 12,691 | 10,491 | 10,491 |
| End Cash Position | 9,216 | 7,573 | 9,461 | 12,691 | 15,400 |
| Net Cash Flow | $-3,475 | $-5,118 | $-3,230 | $2,201 | $4,909 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,138 | -5,459 | -3,230 | -9,128 | -6,420 |
| Capital Expenditure | -9 | -7 | N/A | -8 | -8 |
| Free Cash Flow | -8,147 | -5,466 | -3,230 | -9,136 | -6,428 |